CytomX Therapeutics Inc (CTMX) - Total Liabilities

Latest as of March 2026: $39.41 Million USD

Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has total liabilities worth $39.41 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is CytomX Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.

CytomX Therapeutics Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how CytomX Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See CTMX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

CytomX Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of CytomX Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Zhejiang Zhaofeng Mechanical and Electronic Co Ltd SHE:300695	China	CN¥429.77 Million
Xiangxue Pharmaceutical SHE:300147	China	CN¥6.75 Billion
Beijing Global Safety Technology Co Ltd SHE:300523	China	CN¥2.71 Billion
Groupon Inc NASDAQ:GRPN	USA	$658.33 Million
BEIJ.JINGNENG CL.ERG.HYC1 F:BJ6	Germany	€64.73 Billion
JDM Jingda Mach(Ningbo)Co Ltd SHG:603088	China	CN¥822.81 Million
Charter Hall Social Infrastructure REIT AU:CQE	Australia	AU$807.80 Million
Shanghai Shenda Co Ltd SHG:600626	China	CN¥6.51 Billion

Liability Composition Analysis (2013–2025)

This chart breaks down CytomX Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CTMX market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	10.38	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.12	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.11	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how CytomX Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for CytomX Therapeutics Inc (2013–2025)

The table below shows the annual total liabilities of CytomX Therapeutics Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	$52.56 Million	-56.56%
2024-12-31	$120.99 Million	-51.46%
2023-12-31	$249.24 Million	-28.10%
2022-12-31	$346.64 Million	+38.64%
2021-12-31	$250.03 Million	-31.77%
2020-12-31	$366.44 Million	+26.28%
2019-12-31	$290.17 Million	-11.05%
2018-12-31	$326.23 Million	-0.46%
2017-12-31	$327.75 Million	+171.65%
2016-12-31	$120.65 Million	+69.58%
2015-12-31	$71.15 Million	-53.07%
2014-12-31	$151.60 Million	+159.32%
2013-12-31	$58.46 Million	--

About CytomX Therapeutics Inc

NASDAQ:CTMX USA Biotechnology

Market Cap

$674.88 Million

Market Cap Rank

#10562 Global

#2795 in USA

Share Price

$3.10

Change (1 day)

-5.49%

52-Week Range

$1.76 - $6.75

All Time High

$34.22